Odonate an­nounces 'pos­i­tive' re­sults but faces in­vestor back­lash; Aslan is once again re­cruit­ing clin­i­cal tri­al par­tic­i­pants af­ter months-long wait amid the pan­dem­ic

Odonate Ther­a­peu­tics an­nounced “pos­i­tive top-line re­sults” from a Phase III study of their lead can­cer drug. And sure enough, tese­tax­el im­proved pro­gres­sion-free sur­vival for metasta­t­ic breast can­cer pa­tients over place­bo by 2.9 months.

But in­vestors al­so ap­peared to see some­thing else: a 71% rate of neu­trope­nia for pa­tients in the treat­ment arm, vs. a 8.3% rate for the con­trol group, who re­ceived the gener­ic chemother­a­py capecitabine. The Phase III study cov­ered 685 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER